Global Guillain-Barre Syndrome Therapeutics Market to Reach $850.7 Million by 2030
The global market for Guillain-Barre Syndrome Therapeutics estimated at US$616.5 Million in the year 2023, is expected to reach US$850.7 Million by 2030, growing at a CAGR of 4.7% over the analysis period 2023-2030. Intravenous Immunoglobulin Therapy, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$490.1 Million by the end of the analysis period. Growth in the Plasma Exchange Therapy segment is estimated at 4.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $183.8 Million, While China is Forecast to Grow at 4.3% CAGR
The Guillain-Barre Syndrome Therapeutics market in the U.S. is estimated at US$183.8 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$148.5 Million by the year 2030 trailing a CAGR of 4.3% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 3.7% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook